Diagnostic and Pharmacocorrection Issues Frailty Syndrome and Pre-Frailty

Abstract

The decline in strength and the decline in the functions of many body systems, which increases with age, is called the problem of frailty syndrome (FS) and is very relevant today. Improving the quality of life at this stage of life has initiated many studies and the ways to solve it remain controversial. The study included 78 patients with  frailty syndrome and pre-frailty, in which half received the drug Tivorel. The drug was administered in a dose of 100 ml intravenously drip 1 time a day, for 15 days. The effectiveness of the drug, in addition to subjective and instrumental methods, was evaluated by indicators of the content of the hormone DHEAs and the VEGF signaling protein in blood plasma. It was found that they have a correlation with all clinical indicators - dynamometry, Lawton and FAS scales in patients with  pre-frailty. At the same time, patients with FS revealed a correlation between the content of the hormone DHEAs and the VEGF signaling protein with indicators of muscle strength and the severity of fatigue on the FAS scale. The greatest effectiveness of the drug Tivorel was noted in the age groups of 60-70 years and 71-80 years.